SAB Biotherapeutics (SABS) News Today $2.47 -0.32 (-11.47%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$2.47 +0.00 (+0.16%) As of 09/19/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is SAB Biotherapeutics Dropping Today?Toggle Visibility of Why Is SAB Biotherapeutics Dropping Today?SAB Biotherapeutics, Inc. (NASDAQ:SABS) shares are trading lower as investors weigh recent clinical updates and a flurry of analyst actions. Below is a summary of the latest developments that could influence SABS stock. Positive Sentiment: SAB highlighted multiple data presentations at the European Association for the Study of Diabetes (EASD), showcasing pipeline progress and engaging T1D thought leaders ahead of its Phase 2b SAFEGUARD study launch. Article Title Positive Sentiment: SAB Biotherapeutics initiated its Phase 2b SAFEGUARD trial for SAB-142 in new-onset Stage 3 autoimmune T1D patients, leveraging EASD meetings to engage key investigators. Article Title Positive Sentiment: Chardan Capital reaffirmed its “Buy” rating on SABS with a $12.00 price target, implying roughly 386% upside from current levels. Article Title Positive Sentiment: Leerink Partners initiated coverage of SAB Biotherapeutics with an “Outperform” recommendation and later upgraded to “Strong‐Buy,” projecting EPS improvements from FY 2025 through FY 2029 (including a positive EPS in FY 2029). Article Title | Coverage Initiated at Leerink Partners Posted 1+ days agoAI Generated. May Contain Errors. SABS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating3 hours ago | americanbankingnews.comChardan Capital Reiterates "Buy" Rating for SAB Biotherapeutics (NASDAQ:SABS)4 hours ago | americanbankingnews.comSAB Biotherapeutics (NASDAQ:SABS) Stock Rating Upgraded by Leerink PartnrsSeptember 20 at 4:37 AM | americanbankingnews.comQ3 Earnings Forecast for SABS Issued By Leerink PartnrsSeptember 20 at 2:09 AM | americanbankingnews.comSAB Biotherapeutics highlights data in multiple presentations at EASDSeptember 19 at 3:43 PM | msn.comSAB BIO Highlights Data in Multiple Presentations at EASDSeptember 19 at 7:24 AM | globenewswire.comSAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated at Leerink PartnersSeptember 19 at 2:16 AM | americanbankingnews.comLeerink Partners Initiates Coverage of SAB Biotherapeutics (SABS) with Outperform RecommendationSeptember 18 at 6:36 AM | msn.comSAB Biotherapeutics initiated with an Outperform at LeerinkSeptember 17, 2025 | msn.comSAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of DiabetesSeptember 3, 2025 | markets.businessinsider.comSAB Biotherapeutics files to sell 250M shares of common stock for holdersSeptember 2, 2025 | msn.comSAB BIO Reports Second Quarter Financial Results and Highlights Company UpdatesAugust 7, 2025 | globenewswire.comSAB BIO Announces Oversubscribed $175 Million Private PlacementJuly 21, 2025 | globenewswire.comSABS - SAB Biotherapeutics Inc Sustainability | MorningstarJuly 19, 2025 | morningstar.comMSAB Biotherapeutics Holds Annual Stockholders MeetingJuly 18, 2025 | msn.comSAB Biotherapeutics Inc (SABS) - Investing.comJuly 8, 2025 | investing.comSABS - SAB Biotherapeutics Inc Chart - MorningstarJuly 4, 2025 | morningstar.comMSAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesMay 9, 2025 | finanznachrichten.deSAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesMay 9, 2025 | globenewswire.comCraig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)April 3, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial ResultsApril 2, 2025 | finanznachrichten.deSAB Biotherapeutics price target lowered to $20 from $25 at ChardanApril 2, 2025 | markets.businessinsider.comSAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024March 31, 2025 | markets.businessinsider.comSAB BIO Reports Full Year 2024 Operating and Financial ResultsMarch 31, 2025 | globenewswire.comSAB BIO to Participate in Upcoming Investor ConferencesJanuary 31, 2025 | globenewswire.comStrong Buy Recommendation for SAB-142: Promising Phase 1 Results and Future Market Potential in T1D TreatmentJanuary 29, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 29, 2025 | finanznachrichten.deSAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 28, 2025 | globenewswire.comSAB Biotherapeutics (SABS) Gets a Buy from Craig-HallumJanuary 24, 2025 | markets.businessinsider.comSAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D TherapyJanuary 23, 2025 | globenewswire.comSAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To ConsiderDecember 23, 2024 | finance.yahoo.comSAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)November 9, 2024 | finance.yahoo.comPromising Outlook for SAB Biotherapeutics’ SAB-142 in Type 1 Diabetes Treatment Drives Buy RatingNovember 7, 2024 | markets.businessinsider.comSAB BIO Announces Third Quarter 2024 Financial Results and Provides Company UpdateNovember 6, 2024 | globenewswire.comCraig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)October 15, 2024 | markets.businessinsider.comCraig-Hallum Initiates Coverage of SAB Biotherapeutics (SABS) with Buy RecommendationOctober 10, 2024 | msn.comSAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash WiselySeptember 23, 2024 | finance.yahoo.comSAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare ConferenceSeptember 13, 2024 | globenewswire.comSAB Biotherapeutics (SABS) Gets a Buy from OppenheimerSeptember 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)September 11, 2024 | markets.businessinsider.comSAB BIO to Present at the European Association for the Study of Diabetes 60th Annual MeetingSeptember 4, 2024 | globenewswire.comBuy Rating on SAB Biotherapeutics: Promising Developments in Type 1 Diabetes TreatmentAugust 29, 2024 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company UpdatesAugust 10, 2024 | finanznachrichten.deAnalysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and SAB Biotherapeutics (SABS)August 10, 2024 | markets.businessinsider.comSABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024August 9, 2024 | investorplace.comSAB BIO Announces Second Quarter 2024 Financial Results and Provides Company UpdatesAugust 8, 2024 | globenewswire.comSAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 DiabetesAugust 7, 2024 | finanznachrichten.deSAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 DiabetesAugust 5, 2024 | globenewswire.comEx-Wells Fargo investment banker named CFO of pharma companyJuly 31, 2024 | bizjournals.comSAB BIO Appoints Lucy To as Chief Financial OfficerJuly 31, 2024 | globenewswire.com Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SABS Media Mentions By Week SABS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SABS News Sentiment▼0.760.78▲Average Medical News Sentiment SABS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SABS Articles This Week▼171▲SABS Articles Average Week Get the Latest News and Ratings for SABS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CRIS News Today BOLT News Today AMGN News Today GILD News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today INCY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SABS) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
